{"id":169833,"date":"2025-08-06T08:46:10","date_gmt":"2025-08-06T12:46:10","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169833"},"modified":"2025-08-11T01:36:40","modified_gmt":"2025-08-11T05:36:40","slug":"aurobindo-pharma-ltd-q1-fy26-earnings-results-revenue-up-4-net-profit-falls-10-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q1-fy26-earnings-results-revenue-up-4-net-profit-falls-10-yoy\/","title":{"rendered":"Aurobindo Pharma Ltd Q1 FY26 Earnings Results"},"content":{"rendered":"<div class=\"erp-sidecar:h-fit erp-sidecar:pb-0 mx-auto h-full\">\n<div class=\"relative border-borderMain\/50 ring-borderMain\/50 divide-borderMain\/50 dark:divide-borderMainDark\/50 dark:ring-borderMainDark\/50 dark:border-borderMainDark\/50 bg-base\">\n<div class=\"\">\n<div>\n<div>\n<div>\n<div class=\"erp-sidecar:min-h-[var(--sidecar-content-height)] erp-tab:min-h-screen min-h-[var(--page-content-height-without-header)] border-borderMain\/50 ring-borderMain\/50 divide-borderMain\/50 dark:divide-borderMainDark\/50 dark:ring-borderMainDark\/50 dark:border-borderMainDark\/50 bg-transparent\">\n<div class=\"isolate mx-auto md:pt-6 px-md\">\n<div class=\"pb-md mx-auto pt-5 md:pb-12 max-w-threadContentWidth\">\n<div class=\"relative\">\n<div class=\"gap-y-sm flex flex-col\">\n<div class=\"gap-y-lg mt-3 flex flex-col first:mt-0\">\n<div class=\"border-borderMain\/50 ring-borderMain\/50 divide-borderMain\/50 dark:divide-borderMainDark\/50 dark:ring-borderMainDark\/50 dark:border-borderMainDark\/50 bg-transparent\">\n<div class=\"gap-y-sm md:gap-y-md flex flex-col\">\n<div class=\"relative font-sans text-base text-foreground selection:bg-super\/50 selection:text-foreground dark:selection:bg-super\/10 dark:selection:text-super\">\n<div class=\"min-w-0 break-words [word-break:break-word]\">\n<div id=\"markdown-content-4\" class=\"gap-y-md after:clear-both after:block after:content-['']\" dir=\"auto\">\n<div class=\"relative\">\n<div class=\"prose text-pretty dark:prose-invert inline leading-normal break-words min-w-0 [word-break:break-word] prose-strong:font-medium\">\n<p class=\"my-0 py-2\">Aurobindo Pharma Limited is a key player in the pharmaceutical industry. It manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company supports global healthcare with a broad product portfolio that serves both developed and emerging markets.<\/p>\n<p class=\"my-0 py-2\"><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/dd3e24d6-efee-4b4f-a7ae-6eb284961b63.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Financial Highlights<\/strong><\/a><\/p>\n<p class=\"my-0 py-2\">In Q1 FY26, Aurobindo Pharma reported revenue of \u20b97,868 crore, up 3.98% year-on-year (YoY) from \u20b97,567 crore in Q1 FY25. Total expenses rose 4.72% YoY to \u20b96,769 crore from \u20b96,464 crore. However, consolidated net profit (PAT) declined 10.24% to \u20b9824 crore from \u20b9918 crore. Earnings per share (EPS) also dropped 10.26% to \u20b914.08 compared to \u20b915.69 YoY.<\/p>\n<p class=\"my-0 py-2\"><strong>Operational and Strategic Update<\/strong><\/p>\n<p class=\"my-0 py-2\">The modest revenue growth was driven by stable sales in key markets and strong demand for generics and APIs. This reflects continued end-market demand for essential medicines alongside new product launches. However, total expenses grew faster than revenue due to higher input costs, increased investment in research and development (R&amp;D), and elevated operational expenses. These cost pressures reduced operating margins.<\/p>\n<p class=\"my-0 py-2\">The double-digit decline in net profit and EPS highlights margin challenges, likely due to rising production costs and less favorable product mix or pricing. Aurobindo Pharma remains focused on portfolio optimization by diversifying products and maintaining leadership across multiple therapeutic areas in both regulated and semi-regulated markets. Regulatory compliance, manufacturing excellence, and supply chain efficiency continue to be central priorities.<\/p>\n<p class=\"my-0 py-2\"><strong>R&amp;D and Pipeline Development<\/strong><\/p>\n<p class=\"my-0 py-2\">The company is investing steadily in R&amp;D to support its product pipeline for the US and global markets. These efforts are key to driving future growth and new product launches.<\/p>\n<p class=\"my-0 py-2\"><strong>Strategic Initiatives<\/strong><\/p>\n<p class=\"my-0 py-2\">Aurobindo is working to improve operational efficiency, control manufacturing costs, and expand into specialty and value-added products. These initiatives aim to strengthen long-term competitiveness and profitability.<\/p>\n<p class=\"my-0 py-2\"><strong>Corporate Developments and Outlook<\/strong><\/p>\n<p class=\"my-0 py-2\"><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/dd3e24d6-efee-4b4f-a7ae-6eb284961b63.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> results reflect industry challenges such as cost inflation and competitive pricing, even though demand remains healthy. The company\u2019s operational focus and innovation are essential for navigating the evolving pharmaceutical landscape.<\/p>\n<p class=\"my-0 py-2\">Looking ahead, Aurobindo Pharma is committed to expanding its pipeline, enhancing regulatory compliance, and optimizing costs. By concentrating on high-growth markets, improving operations, and investing in R&amp;D and manufacturing capacity, it aims to sustain growth and create value for shareholders through FY26 and beyond.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-169834\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png\" alt=\"\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<p>&nbsp;<\/p>\n<p>To view the company&#8217;s previous earnings, <a href=\"https:\/\/44.250.171.167\/symbol\/auropharma\/\">click here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma Limited is a key player in the pharmaceutical industry. It manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company supports global healthcare with a broad product portfolio that serves both developed and emerging markets. Financial Highlights In Q1 FY26, Aurobindo Pharma reported revenue of \u20b97,868 crore, up 3.98% [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":169834,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-169833","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":172164,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":169833,"position":0},"title":"Aurobindo Pharma Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 6, 2025","format":false,"excerpt":"Aurobindo Pharma Ltd, a leading pharmaceutical company focused on active pharmaceutical ingredients and generic pharmaceuticals, reported a steady Q2FY26 financial performance with revenues rising 6.3% year-on-year to \u20b98,286 crore. Consolidated net profit increased by 3.8% to \u20b9848 crore, reflecting resilience in key markets such as the US and Europe. Key\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168736,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q4fy25-0-fall-in-profits\/","url_meta":{"origin":169833,"position":1},"title":"Aurobindo Pharma Ltd Q4FY25; 0% fall in Profits","author":"Divyansh_Kasana","date":"June 10, 2025","format":false,"excerpt":"Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159) Financial Results: Aurobindo Pharma Ltd reported Revenues for Q4FY25 of \u20b98,382.00 Crores up from \u20b97,580.00 Crore year on year, a rise of 10.58%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":167130,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q3fy25-10-fall-in-profits\/","url_meta":{"origin":169833,"position":2},"title":"Aurobindo Pharma Ltd Q3FY25; 10% fall in Profits","author":"Divyansh_Kasana","date":"February 28, 2025","format":false,"excerpt":"Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159) Financial Results: Aurobindo Pharma Ltd reported Revenues for Q3FY25 of \u20b97,979.00 Crores up from \u20b97,352.00 Crore year on year, a rise of 8.53%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/F.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":163926,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q1fy25-61-rise-in-profits\/","url_meta":{"origin":169833,"position":3},"title":"Aurobindo Pharma Ltd Q1FY25; 61% rise in Profits","author":"Divyansh_Kasana","date":"August 19, 2024","format":false,"excerpt":"Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. Financial Results: Aurobindo Pharma Ltd reported Revenues for Q1FY25 of \u20b97,567.00 Crores up from \u20b96,851.00 Crore year on year, a rise of 10.45%. Total Expenses for Q1FY25 of \u20b96,464.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-125.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170207,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-q1-fy26-earnings-results\/","url_meta":{"origin":169833,"position":4},"title":"Astrazeneca Pharma Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 15, 2025","format":false,"excerpt":"AstraZeneca Pharma India Limited is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9826 crore, up 29.06% year-on-year (YoY) from \u20b9640 crore in Q1 FY25. Total Expenses: \u20b9726 crore, up 20.40% YoY from \u20b9603 crore. Consolidated\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ASTRAZEN Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":162090,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q4fy24-79-rise-in-profits\/","url_meta":{"origin":169833,"position":5},"title":"Aurobindo Pharma Ltd Q4FY24; 79% rise in Profits","author":"Divyansh_Kasana","date":"June 11, 2024","format":false,"excerpt":"Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159) Financial Results: Aurobindo Pharma Ltd reported Revenues for Q4FY24 of \u20b97,580.00 Crores up from \u20b96,473.00 Crore year on year, a rise of 17.1%. Total Expenses for\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-105.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-105.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-105.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-105.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-105.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-105.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169833"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169833\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/169834"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}